Publications

Dupouy B, Karpstein T, Häberli C, Cal M, Rottmann M, Mäser P, Keiser J, Elhabiri M, Davioud-Charvet E. Synthesis of 1,2,3-triazole-methyl-menadione derivatives: evaluation of electrochemical and antiparasitic properties against two blood-dwelling parasites. ChemMedChem. 2025;20(6):e202400731. DOI: 10.1002/cmdc.202400731

Dziwornu G.A, Attram H.D, Häberli C, Masike K, Njoroge M, Keiser J. Benzimidazole analogues active against adult Schistosoma mansoni: SAR analyses, in vivo efficacy in mice, and preliminary mechanistic studies as potential inhibitors of hemozoin formation. Eur J Med Chem. 2025;284:117186. DOI: 10.1016/j.ejmech.2024.117186

Lo N.C, Addiss D.G, Buonfrate D, Amor A, Anegagrie M, Bisoffi Z, Bradbury R.S, Keiser J, Kepha S, Khieu V, Krolewiecki A, Mbonigaba J.B, Muñoz J, Mutapi F, Novela V, Vaz Nery S, Coffeng L.E, de Vlas S.J, Bartoszko J, Moja L, Mupfasoni D, Montresor A. Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis. Lancet Infect Dis. 2025;25(3):e146-e152. DOI: 10.1016/s1473-3099(24)00595-4

Malan D, Van Niekerk S, Häberli C, Keiser J, Van der Kooy F. In vitro antischistosomal activity of Artemisia species. Acta Trop. 2025;262:107535. DOI: 10.1016/j.actatropica.2025.107535

Ueberall M.E, Berchthold M, Häberli C, Lindemann S, Spangenberg T, Keiser J, Grevelding C.G. Merck Open Global Health Library in vitro screening against Schistosoma mansoni identified two new substances with antischistosomal activities for further development. Parasit Vectors. 2025;18:40. DOI: 10.1186/s13071-024-06648-0

Venkatesan A, Chen R, Bär M, Schneeberger P.H.H, Reimer B, Hürlimann E, Coulibaly J.T, Ali S.M, Sayasone S, Soghigian J, Keiser J, Gilleard J.S. Trichuriasis in human patients from Côte d'Ivoire caused by novel Trichuris incognita species with low sensitivity to albendazole/ivermectin combination treatment. Emerg Infect Dis. 2025;31(1):104-114. DOI: 10.3201/eid3101.240995

Ajayi D.T, Orherhe O.M, Pillai G.C, Mouksassi S, Steffens B, Bräm D, Sprecher V, Hofmann D, Buettcher M, Coulibaly J.T, Ali S.M, Keiser J, Pfister M. Pharmacometric analysis to describe pharmacokinetics and exposure-efficacy response of ivermectin in adolescents infected with Trichuris trichiura. J Clin Pharmacol. 2024(in press). DOI: 10.1002/jcph.6158

Brooker S.J, Keiser J, Bundy D.A.P. Soil-transmitted helminths (geohelminths). In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J,Garcia P.J, eds. Manson's Tropical Diseases, 772-796. Amsterdam: Elsevier, 2024. DOI: 10.1016/B978-0-7020-7959-7.00060-9

Cesar-Rodo E, Dupouy B, Häberli C, Strub J.M, Williams D.L, Mäser P, Rottmann M, Keiser J, Lanfranchi D.A, Davioud-Charvet E. Regioselective synthesis of potential non-quinonoid prodrugs of plasmodione: antiparasitic properties against two hemoglobin-feeding parasites and drug metabolism studies. Molecules. 2024;29(22):5268. DOI: 10.3390/molecules29225268

Davie T, Serrat X, Imhof L, Snider J, Štagljar I, Keiser J, Hirano H, Watanabe N, Osada H, Fraser A.G. Identification of a family of species-selective complex I inhibitors as potential anthelmintics. Nat Commun. 2024;15:3367. DOI: 10.1038/s41467-024-47331-3

Dommann J, Keiser J, Garneau J, Gandelin A, Casanova C, Keller P.M, Sayasone S, Vonaesch P, Schneeberger P.H.H. Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation. Commun Biol. 2024;7:1566. DOI: 10.1038/s42003-024-07135-z

Dommann J, Kerbl-Knapp J, Albertos Torres D, Egli A, Keiser J, Schneeberger P.H.H. A novel barcoded nanopore sequencing workflow of high-quality, full-length bacterial 16S amplicons for taxonomic annotation of bacterial isolates and complex microbial communities. mSystems. 2024;9(10):e0085924. DOI: 10.1128/msystems.00859-24

Emerson P.M, Evans D, Freeman M.C, Hanson C, Kalua K, Keiser J, Krolewiecki A, Leonard L, Levecke B, Matendechero S, Means A.R, Montresor A, Mupfasoni D, Pullan R.L, Rotondo L.A, Stephens M, Sullivan K.M, Walson J.L, Williams T, Utzinger J. Need for a paradigm shift in soil-transmitted helminthiasis control: targeting the right people, in the right place, and with the right drug(s). PLoS Negl Trop Dis. 2024;18(10):e0012521. DOI: 10.1371/journal.pntd.0012521

Fuchs N, Zimmermann R.A, Schwickert M, Gunkel A, Zimmer C, Meta M, Schwickert K, Keiser J, Häberli C, Kiefer W, Schirmeister T. Dual strategy to design new agents targeting Schistosoma mansoni: advancing phenotypic and SmCB1 inhibitors for improved efficacy. ACS Infect Dis. 2024;10(5):1664-1678. DOI: 10.1021/acsinfecdis.4c00020

González Cabrera D, Keiser J, Spangenberg T. Analysis of the physicochemical properties of anti-schistosomal compounds to identify next-generation leads. ACS Med Chem Lett. 2024;15(5):626-630. DOI: 10.1021/acsmedchemlett.4c00026

Gordon C.A, Utzinger J, Muhi S, Becker S.L, Keiser J, Khieu V, Gray D.J. Strongyloidiasis. Nat Rev Dis Primers. 2024;10:6. DOI: 10.1038/s41572-023-00490-x

Grolimund C.M, Utzinger J, Coulibaly J.T, Sayasone S, Ali S.M, Keiser J, Vounatsou P. Modeling transmission mechanism to infer treatment efficacy of different drugs and combination therapy against Trichuris trichiura. Sci Rep. 2024;14:23543. DOI: 10.1038/s41598-024-73164-7

Keiser J, Bouchery T. A step forward in the journey towards hookworm vaccines. Lancet Infect Dis. 2024;24(7):673-674. DOI: 10.1016/s1473-3099(24)00145-2

Kuevi D.N.O, Keiser J, Häberli C, Owusu-Senyah A.K, Ahiabu M.K. In vitro antischistosomal activity of Bridelia ferruginea, Clausena anisata, Khaya senegalensis, and Vernonia amygdalina. J Trop Med. 2024;2024(1):8074291. DOI: 10.1155/2024/8074291

Leas D.A, Keiser J, Charman S.A, Shackleford D.M, Jones J.O, Campbell M, Chen G, Katneni K, Patil R, Hu M, Pham T, Häberli C, Schulze T.T, Neville A.J, Wang X, Dong Y, Davis P.H, Vennerstrom J.L. Single-dose drug development candidate for schistosomiasis. ACS Infect Dis. 2024;10(11):3963-3972. DOI: 10.1021/acsinfecdis.4c00677

Lotz C.N, Krollenbrock A, Imhof L, Riscoe M, Keiser J. Robenidine derivatives as potential antischistosomal drug candidates. Int J Parasitol Drugs Drug Resist. 2024;25:100546. DOI: 10.1016/j.ijpddr.2024.100546

Palmeirim M.S, Hürlimann E, Beinamaryo P, Kyarisiima H, Nabatte B, Hattendorf J, Steinmann P, Keiser J. Efficacy and safety of albendazole alone versus albendazole in combination with ivermectin for the treatment of Trichuris trichiura infections: an open-label, randomized controlled superiority trial in south-western Uganda. PLoS Negl Trop Dis. 2024;18(11):e0012687. DOI: 10.1371/journal.pntd.0012687

Pillay-Fuentes Lorente V, Nwogu-Attah J.N, Steffens B, Bräm D, Sprecher V, Hofmann D, Buettcher M, Pillai G, Mouksassi S, Coulibaly J, Pfister M, Keiser J. Understanding drug exposure and Trichuris trichiura cure rates: a pharmacometric approach for albendazole-ivermectin co-medication in Tanzania and Côte d'Ivoire. Drugs R D. 2024;24(2):331-340. DOI: 10.1007/s40268-024-00476-4

Qian M.B, Keiser J, Utzinger J, Zhou X.N. Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control. Clin Microbiol Rev. 2024;37(1):e0000923. DOI: 10.1128/cmr.00009-23

Ren R, Leas D.A, Häberli C, Cal M, Chen G, Katneni K, Dong Y, Kaiser M, Keiser J, Charman S.A, Vennerstrom J.L. Medium-ring keto bislactams with antischistosomal activity. J Med Chem. 2024;67(20):18235-18246. DOI: 10.1021/acs.jmedchem.4c01532

Shanley H.T, Taki A.C, Nguyen N, Wang T, Byrne J.J, Ang C.S, Leeming M.G, Nie S, Williamson N, Zheng Y, Young N.D, Korhonen P.K, Hofmann A, Chang B.C.H, Wells T.N.C, Häberli C, Keiser J, Jabbar A, Sleebs B.E, Gasser R.B. Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity. Int J Parasitol Drugs Drug Resist. 2024;24:100522. DOI: 10.1016/j.ijpddr.2024.100522

Sprecher V.P, Hofmann D, Savathdy V, Xayavong P, Norkhankhame C, Huy R, Khieu V, Sayasone S, Hattendorf J, Keiser J. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial. Lancet Infect Dis. 2024;24(2):196-205. DOI: 10.1016/s1473-3099(23)00507-8

Stettler M, Lotz C, Probst A, Marreros N, Lundström-Stadelmann B, Frey C.F, Keiser J, Hofer A, Hoby S. Safety and pharmacokinetics of praziquantel in European pond turtles (Emys orbicularis). J Zoo Wildl Med. 2024;54(4):728-737. DOI: 10.1638/2023-0031

Taylor L, Ahmada A.A, Ali M.S, Ali S.M, Hattendorf J, Mohammed I.S, Keiser J. Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial. Lancet. 2024;404(10453):683-691. DOI: 10.1016/s0140-6736(24)01403-x

Vaillant M.T, Philippy F, Neven A, Barré J, Bulaev D, Olliaro P.L, Utzinger J, Keiser J, Garba A.T. Diagnostic tests for human Schistosoma mansoni and Schistosoma haematobium infection: a systematic review and meta-analysis. Lancet Microbe. 2024;5:e366-e378. DOI: 10.1016/s2666-5247(23)00377-4

van Beek A.E, Jeanguenat H, Häberli C, Pouw R.B, Lamers C, Pál G, Gál P, Schmidt C.Q, Ricklin D, Keiser J. Praziquantel and factor H recruitment differentially affect the susceptibility of Schistosoma mansoni to complement-mediated damage. Front Immunol. 2024;15:1474358. DOI: 10.3389/fimmu.2024.1474358

Welsche S, Schneeberger P.H.H, Hattendorf J, Sayasone S, Hürlimann E, Keiser J. Egg excretion patterns of soil-transmitted helminth infections in humans following albendazole-ivermectin and albendazole treatment. PLoS Negl Trop Dis. 2024;18(3):e0012073. DOI: 10.1371/journal.pntd.0012073

Biendl S, Häberli C, Chen G, Wang W, Zhong L, Saunders J, Pham T, Wang X, Wu J, Charman S.A, Vennerstrom J.L, Keiser J. In vitro and in vivo antischistosomal activity profiling and pharmacokinetics of ozonide carboxylic acids. ACS Infect Dis. 2023;9(3):643-652. DOI: 10.1021/acsinfecdis.2c00581

Cappuccino C, Spoletti E, Renni F, Muntoni E, Keiser J, Voinovich D, Perissutti B, Lusi M. Co-crystalline solid solution affords a high-soluble and fast-absorbing form of praziquantel. Mol Pharm. 2023;20(4):2009-2016. DOI: 10.1021/acs.molpharmaceut.2c00984

Coffeng L.E, Vlaminck J, Cools P, Denwood M, Albonico M, Ame S.M, Ayana M, Dana D, Cringoli G, de Vlas S.J, Fenwick A, French M, Kazienga A, Keiser J, Knopp S, Leta G, Matoso L.F, Maurelli M.P, Montresor A, Mirams G, Mekonnen Z, Corrêa-Oliveira R, Pinto S.A, Rinaldi L, Sayasone S, Steinmann P, Thomas E, Vercruysse J, Levecke B. A general framework to support cost-efficient fecal egg count methods and study design choices for large-scale STH deworming programs-monitoring of therapeutic drug efficacy as a case study. PLoS Negl Trop Dis. 2023;17(5):e0011071. DOI: 10.1371/journal.pntd.0011071

Coulibaly J.T, Silue K.D, Armstrong M, Díaz de León Derby M, D'Ambrosio M.V, Fletcher D.A, Keiser J, Fisher K, Andrews J.R, Bogoch I.I. High sensitivity of mobile phone microscopy screening for Schistosoma haematobium in Azaguié, Côte d'Ivoire. Am J Trop Med Hyg. 2023;108(1):41-43. DOI: 10.4269/ajtmh.22-0527

D'Abbrunzo I, Bianco E, Gigli L, Demitri N, Birolo R, Chierotti M.R, Škorić I, Keiser J, Häberli C, Voinovich D, Hasa D, Perissutti B. Praziquantel meets Niclosamide: a dual-drug antiparasitic cocrystal. Int J Pharm. 2023;644:123315. DOI: 10.1016/j.ijpharm.2023.123315

Easland E, Biendl S, Keiser J. Development of a hookworm egg hatching assay to determine the ovicidal effects of anthelminthics. Parasit Vectors. 2023;16:157. DOI: 10.1186/s13071-023-05771-8

Friedrich L, Park S.K, Ballard P, Ho Baeurle T.H, Maillard D, Bödding M, Keiser J, Marchant J.S, Spangenberg T. Metabolism of (R)-praziquantel versus the activation of a Parasite Transient Receptor Potential Melastatin ion channel. ChemMedChem. 2023;18(18):e202300140. DOI: 10.1002/cmdc.202300140

Hürlimann E, Hofmann D, Keiser J. Ivermectin and moxidectin against soil-transmitted helminth infections. Trends Parasitol. 2023;39(4):272-284. DOI: 10.1016/j.pt.2023.01.009